Description

+ Include: 9 videos, size: 17.5 GB

+ Target Audience: nephrologists, clinical trialists, principal investigators, satisticians

+ Information:

The Kidney Disease Clinical Trialists (KDCT) 8th Edition 2024 Workshop will be held on March 15-16, 2024, in Washington DC. This high-level think tank event will feature an exceptional expert faculty and a limited number of attendees, including distinguished nephrologists, clinical trialists, principal investigators, and statisticians from academia, R&D pharma and device companies, NIH, EMA, PMDA, FDA, and payers.

The workshop aims to foster an international exchange of ideas on trial design, conduct, ethics, interpretation, approvability, and implementation encompassing drugs, devices, biomarkers, and therapeutic strategies for kidney disease

The Kidney Disease Clinical Trialists (KDCT) 8th Edition 2024 Workshop is designed for a select group of professionals involved in kidney disease research and clinical trials. The target audience includes:

Nephrologists
Clinical trialists
Principal investigators
Statisticians
Researchers from academia
Professionals from R&D pharma and device companies
Representatives from regulatory bodies like NIH, EMA, PMDA, and FDA
Payers
Patient advocates

This workshop aims to foster an international exchange of ideas on trial design, conduct, ethics, interpretation, approvability, and implementation of therapeutic strategies for kidney disease.

+ Topics:

SESSION 1 EGFR SLOPE VS EGFR DELTA AS AN ENDPOINT PROS AND CONS.mp4
SESSION 2 COMBINATION THERAPY IN CKD.mp4
SESSION 3 Focus on IGAN.mp4
SESSION 4 Shifting earlg deveIOpment trials from the EGFR UACR ratio paradigm to a multiplexed biomarker enabled strategy.mp4
SESSION 5 Are simplified consents desirable achievable.mp4
SESSION 6 Dialysis and Vascular Access.mp4
SESSION 7 How to assess the renal benefit of weight loss drugs (i.e.drugs that can affect lean bodg mass).mp4
SESSION 8 Endpoints in AKI trials to guide generation of Core Outcome data Set.mp4
SESSION 9 Developing Core Outcomes Sets in AKI trials.mp4